Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2016

View Archived Issues

Role of SUMOylated SOD2 in alcoholic liver disease and liver cancer

FDA expands indication for FluLaval influenza vaccine

FDA grants fast track designation to Oragenics' AG-013

IBT receives positive recommendation to continue phase II trial of IBP-9414

FDA lifts partial clinical hold on trials evaluating Aduro Biotech's LADD platform

AbbVie discontinues development program under Halozyme collaboration

Intarcia Therapeutics submits NDA for ITCA-650

Janssen Pharmaceutica patents TARPgamma8 inhibitors

WHO announces global health funding for RTS,S malaria vaccine

Janssen R&D Ireland discloses agents for RSV infection

Actelion Pharmaceuticals describes TPHI1 inhibitors

Rosetta Genomics enters research agreement with Sheba Medical Center

FDA approves Darzalex in combination with standard of care for relapsed multiple myeloma

Roche presents HBsAg and HBV DNA production inhibitors

FDA approves Soliqua for type 2 diabetes

FDA lifts partial clinical hold on head and neck cancer trials of durvalumab

Midatech receives payment under Emergex license contract

Pan-Nox inhibitor for diabetic nephropathy

Novo Nordisk's Xultophy wins FDA approval for type 2 diabetes

Sandoz's epoetin alfa biosimilar for renal anemia

Regulus chemically modified oligonucleotide for Alport syndrome

Novel Zika virus vaccine based on the Zika E glycoprotein

Phase I clinical testing of the hookworm vaccine NA-APR-1

License and collaboration between Arrowhead and Amgen closed

Spectrum Pharmaceuticals receives CRL from FDA on Qapzola

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...